Rabbit Recombinant Monoclonal AGXT antibody. Suitable for WB and reacts with Human samples. Cited in 2 publications.
IgG
Rabbit
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9% PBS, 0.05% BSA
Liquid
Monoclonal
ICC/IF | IP | Flow Cyt | WB | |
---|---|---|---|---|
Human | Not recommended | Not recommended | Not recommended | Tested |
Mouse | Not recommended | Not recommended | Not recommended | Predicted |
Rat | Not recommended | Not recommended | Not recommended | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 - 1/10000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Select an associated product type
Serine--pyruvate aminotransferase, SPT, Alanine--glyoxylate aminotransferase, AGT, AGXT, SPAT, AGT1
Rabbit Recombinant Monoclonal AGXT antibody. Suitable for WB and reacts with Human samples. Cited in 2 publications.
IgG
Rabbit
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9% PBS, 0.05% BSA
Liquid
Monoclonal
EPR13232-59
Tissue culture supernatant
Blue Ice
1-2 weeks
+4°C
-20°C
Upon delivery aliquot
Avoid freeze / thaw cycle
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This supplementary information is collated from multiple sources and compiled automatically.
The biological target AGXT also known as alanine-glyoxylate aminotransferase plays an important role in human metabolism. It is a liver-specific enzyme with an approximate molecular weight of 43 kDa. AGXT is expressed primarily in liver peroxisomes where it catalyzes the transamination reaction that converts glyoxylate to glycine. This enzymatic activity is important for detoxifying glyoxylate which otherwise could accumulate and result in harmful effects. The expression level and activity of AGXT can be influenced by various metabolic conditions.
The conversion of glyoxylate to glycine mediated by AGXT helps in maintaining cellular homeostasis. AGXT is not part of large protein complexes but it directly influences the pathways leading to amino acid metabolism. By converting glyoxylate into glycine this enzyme plays a part in managing the precursors necessary for the biosynthesis of other important biomolecules including serine and pyruvate. As glyoxylate is an important intermediary its conversion is essential for metabolic flux.
AGXT has a significant role in the glyoxylate metabolic pathway and the glycine serine and threonine metabolism pathway. In these pathways it works closely with other enzymes like glycine decarboxylase and serine hydroxymethyltransferase. The proper functioning of these pathways ensures efficient energy utilization and detoxification in the human body. Any disruption can affect the balance of amino acid concentrations leading to metabolic disturbances.
AGXT is most prominently linked to primary hyperoxaluria type 1 (PH1) which is a rare genetic condition. In PH1 mutations in the AGXT gene lead to its dysfunctional enzyme causing the accumulation of oxalate and subsequent kidney stone formation and renal failure. The disease connection places AGXT in relation to key proteins involved in oxalate metabolism and renal function such as glycolate oxidase. Understanding AGXT's role in these disorders opens pathways for therapeutic interventions and advanced research into metabolic regulation.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-AGXT antibody [EPR13232-59] (ab178699) at 1/1000 dilution
Lane 1: HepG2 cell lysate at 10 µg
Lane 2: Human fetal liver tissue lysate at 10 µg
Predicted band size: 43 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com